AR106487A1 - Antagonistas de receptores de cgrp - Google Patents
Antagonistas de receptores de cgrpInfo
- Publication number
- AR106487A1 AR106487A1 ARP160103294A ARP160103294A AR106487A1 AR 106487 A1 AR106487 A1 AR 106487A1 AR P160103294 A ARP160103294 A AR P160103294A AR P160103294 A ARP160103294 A AR P160103294A AR 106487 A1 AR106487 A1 AR 106487A1
- Authority
- AR
- Argentina
- Prior art keywords
- cgrp
- receiver antagonists
- antagonists
- cgrp receiver
- cerebrovascular
- Prior art date
Links
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 title 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 abstract 1
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1519194.3A GB201519194D0 (en) | 2015-10-30 | 2015-10-30 | CGRP receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106487A1 true AR106487A1 (es) | 2018-01-17 |
Family
ID=55130446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103294A AR106487A1 (es) | 2015-10-30 | 2016-10-28 | Antagonistas de receptores de cgrp |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9688660B2 (enExample) |
| EP (1) | EP3368526B1 (enExample) |
| JP (1) | JP6874014B2 (enExample) |
| CN (1) | CN108430991B (enExample) |
| AR (1) | AR106487A1 (enExample) |
| AU (1) | AU2016344689A1 (enExample) |
| BR (1) | BR112018008416A2 (enExample) |
| CA (1) | CA3002625A1 (enExample) |
| GB (1) | GB201519194D0 (enExample) |
| IL (1) | IL258894A (enExample) |
| SG (1) | SG11201803382XA (enExample) |
| TW (1) | TW201722936A (enExample) |
| WO (1) | WO2017072723A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519194D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| IL293647A (en) * | 2019-12-17 | 2022-08-01 | Biohaven Pharm Holding Co Ltd | Intranasal pharmaceutical compositions of cgrp inhibitors |
| WO2024046223A1 (zh) * | 2022-08-30 | 2024-03-07 | 熙源安健医药（上海）有限公司 | 吲唑甲酰胺类衍生物及其制备方法和用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2732221B1 (fr) | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue |
| JP3483893B2 (ja) | 1996-09-10 | 2004-01-06 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法 |
| US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| US6294534B1 (en) | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| JP2002517444A (ja) | 1998-06-11 | 2002-06-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作動薬としてのスピロピペリジン誘導体 |
| DE19952146A1 (de) * | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| KR20050008790A (ko) | 2002-06-05 | 2005-01-21 | 브리스톨-마이어스 스큅 컴퍼니 | 칼시토닌 유전자 관련 펩티드 수용체 길항제 |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| AR046787A1 (es) | 2003-12-05 | 2005-12-21 | Bristol Myers Squibb Co | Agentes antimigrana heterociclicos |
| EP1689493A4 (en) | 2003-12-05 | 2008-04-23 | Bristol Myers Squibb Co | ANTAGONISTS OF THE CALCITONIN GENE RELATED PEPTIDE RECEPTOR |
| DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| US20050233980A1 (en) * | 2004-04-20 | 2005-10-20 | Boehringer Ingelheim International Gmbh | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine |
| DE102004019492A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| KR20070062997A (ko) | 2004-10-13 | 2007-06-18 | 머크 앤드 캄파니 인코포레이티드 | Ｃｇｒｐ 수용체 길항제 |
| WO2006044449A2 (en) | 2004-10-14 | 2006-04-27 | Merck & Co., Inc. | Cgrp receptor antagonists |
| JP2008517916A (ja) | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | Ｃｇｒｐ受容体拮抗薬 |
| EP1770091A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| KR20090021214A (ko) | 2006-06-08 | 2009-02-27 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｇｒｐ-길항제에 의한 위장 장애의 치료 |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| CN102256963B (zh) * | 2008-12-19 | 2014-06-11 | 贝林格尔.英格海姆国际有限公司 | 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺 |
| US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8481546B2 (en) | 2010-03-30 | 2013-07-09 | Bristol-Myers Squibb Company | CGRP receptor antagonist |
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| GB201519194D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
-
2015
- 2015-10-30 GB GBGB1519194.3A patent/GB201519194D0/en not_active Ceased
-
2016
- 2016-10-28 EP EP16808804.5A patent/EP3368526B1/en active Active
- 2016-10-28 CN CN201680063940.2A patent/CN108430991B/zh active Active
- 2016-10-28 US US15/336,893 patent/US9688660B2/en active Active
- 2016-10-28 JP JP2018541593A patent/JP6874014B2/ja active Active
- 2016-10-28 BR BR112018008416A patent/BR112018008416A2/pt not_active Application Discontinuation
- 2016-10-28 AR ARP160103294A patent/AR106487A1/es unknown
- 2016-10-28 AU AU2016344689A patent/AU2016344689A1/en not_active Abandoned
- 2016-10-28 CA CA3002625A patent/CA3002625A1/en not_active Abandoned
- 2016-10-28 TW TW105135025A patent/TW201722936A/zh unknown
- 2016-10-28 WO PCT/IB2016/056519 patent/WO2017072723A1/en not_active Ceased
- 2016-10-28 SG SG11201803382XA patent/SG11201803382XA/en unknown
-
2017
- 2017-05-05 US US15/588,051 patent/US9925178B2/en active Active
-
2018
- 2018-01-29 US US15/882,038 patent/US10166226B2/en active Active
- 2018-04-24 IL IL258894A patent/IL258894A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201722936A (zh) | 2017-07-01 |
| EP3368526A1 (en) | 2018-09-05 |
| SG11201803382XA (en) | 2018-05-30 |
| EP3368526B1 (en) | 2019-12-25 |
| CN108430991B (zh) | 2021-01-05 |
| US20180153876A1 (en) | 2018-06-07 |
| GB201519194D0 (en) | 2015-12-16 |
| JP2018532790A (ja) | 2018-11-08 |
| AU2016344689A1 (en) | 2018-05-17 |
| IL258894A (en) | 2018-06-28 |
| US10166226B2 (en) | 2019-01-01 |
| US20170239236A1 (en) | 2017-08-24 |
| US9925178B2 (en) | 2018-03-27 |
| US9688660B2 (en) | 2017-06-27 |
| BR112018008416A2 (pt) | 2018-10-23 |
| US20170121311A1 (en) | 2017-05-04 |
| WO2017072723A1 (en) | 2017-05-04 |
| JP6874014B2 (ja) | 2021-05-19 |
| CN108430991A (zh) | 2018-08-21 |
| CA3002625A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200209A1 (ar) | مثبطات cd73 | |
| UY36684A (es) | Agonistas de triazol del receptor apj | |
| BR112018008423A2 (pt) | antagonistas do receptor cgrp | |
| CR20180352A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos | |
| AR106487A1 (es) | Antagonistas de receptores de cgrp | |
| IL271266A (en) | Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia | |
| BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
| CL2017003032A1 (es) | Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| MX384833B (es) | Inhibidores de tirosina quinasa de bruton | |
| CO2017002160A2 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| LT3805220T (lt) | Policikliniai karbamoilpiridono dariniai, skirti živ gydymui | |
| EP3810614C0 (en) | BRIDGED COMPOUNDS FOR USE AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | |
| EP4034156A4 (en) | COMBINATION THERAPY WITH CGRP ANTAGONISTS | |
| AR106488A1 (es) | Antagonistas de receptores de cgrp | |
| EA201992147A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| MX2020003507A (es) | Compuestos pirimidinicos inhibidores de (tbk)/(ikk) epsilon y usos de los mismos. | |
| PH12018500282A1 (en) | Cgrp receptor antagonists | |
| EA201990158A1 (ru) | Производные бензодиоксана и их фармацевтическое применение | |
| EP3506925C0 (en) | USE OF CGRP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GLAUCOMA | |
| CL2019001618A1 (es) | Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar. | |
| AR111665A1 (es) | Derivados de 3-metil-pirrolidina-2,5-diona útiles como antagonistas del receptor cgrp | |
| PH12017501214A1 (en) | Cgrp antagonist peptides | |
| MX381323B (es) | Derivado de imidazopirimidina e imidazotriazina, y composición farmacéutica que lo comprende. | |
| UY37339A (es) | Formas de sal de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1himidazol-2-carboxamida y composiciones que las contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |